Cost Of Treatment-Related Adverse Events (TRAES) In Second-Line (2l) Advanced Hepatocellular Carcinoma (AHCC)- Match Adjusted Indirect Comparison (MAIC) Of Nivolumab And Regorafenib
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.590
https://www.valueinhealthjournal.com/article/S1098-3015(17)30924-5/fulltext
Section Title :
Health Care Treatment Studies
Section Order :
560
First Page :
A502
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30924-5&doi=10.1016/j.jval.2017.08.590